Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Alogliptin and Voglibose in Type 2 Diabetes
NCT01263509Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of alogliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoint: Number of Participants With Adverse Events at 52 Weeks. Started Jun 2007; status: completed.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01263509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01263509.